Analyst Reco. ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Real-time Estimate Cboe BZX Other stock markets 13:25:33 2024-05-02 EDT			5-day change	1st Jan Change
17.16 ^USD	+1.33%		+1.60%	+15.11%

04-30	ALX Oncology Holdings Inc. Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer	CI
04-18	Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing	04-18	MT
UBS Adjusts ALX Oncology Price Target to $25 From $27, Maintains Buy Rating	03-13	MT
H.C. Wainwright Adjusts Price Target on ALX Oncology to $20 From $17.50, Keeps Buy Rating	03-11	MT
Piper Sandler Adjusts Price Target on ALX Oncology Holdings to $21 From $11, Maintains Overweight Rating	03-08	MT
Stifel Downgrades ALX Oncology Holdings to Hold From Buy, Adjusts Price Target to $14 From $10	03-08	MT
Jefferies Upgrades ALX Oncology to Buy From Hold, Adjusts Price Target to $18 From $8	12-08	MT
Stifel Trims ALX Oncology Holdings' Price Target to $10 From $11, Maintains Buy Rating	11-14	MT
Piper Sandler Raises Price Target on ALX Oncology to $11 From $8, Maintains Overweight Rating	23-10-11	MT
UBS Adjusts ALX Oncology Price Target to $27 From $29, Maintains Buy Rating	23-10-04	MT
Cantor Fitzgerald Raises Price Target on ALX Oncology to $23 From $18, Maintains Overweight Rating	23-10-04	MT
Cantor Fitzgerald Cuts Price Target on ALX Oncology Holdings to $18 From $22, Maintains Overweight Rating	23-08-14	MT
HC Wainwright Adjusts ALX Oncology Price Target to $16 From $30, Maintains Buy Rating	23-08-11	MT
UBS Adjusts ALX Oncology's Price Target to $29 From $31, Maintains Buy Rating	23-03-15	MT
Credit Suisse Lowers ALX Oncology Holdings' Price Target to $34 From $38, Keeps Outperform Rating	23-03-10	MT
HC Wainwright Adjusts ALX Oncology Price Target to $30 From $65, Maintains Buy Rating	23-03-10	MT
HC Wainwright Lowers Price Target on ALX Oncology Holdings to $65 From $80, Maintains Buy Rating	22-11-09	MT
UBS Adjusts ALX Oncology Price Target to $31 From $37, Maintains Buy Rating	22-08-26	MT
Cantor Fitzgerald Adjusts ALX Oncology Holdings' Price Target to $32 from $60, Maintains Overweight Rating	22-08-09	MT
Credit Suisse Lowers ALX Oncology Holdings' PT to $38 from $43, Notes Increased Discount Rate to Reflect Greater Uncertainty on Interest Rate/Inflation; Keeps Outperform Rating	22-08-09	MT
Stifel Adjusts Price Target on ALX Oncology Holdings to $16 From $35, Reiterates Buy Rating	22-06-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Analyst Reco.

Filters